Kaos Capital宣布，计划在Capricor Therapeutics（NASDAQ: CAPR）提名两名独立董事候选人，同时推动成立一个由董事会主导的并购与战略替代方案委员会。此举标志着该投资机构对Capricor治理结构及战略方向提出了更为积极的介入姿态。
Kaos Capital表示，此举旨在强化董事会的独立性与专业能力，从而为公司的长期价值创造提供更具前瞻性的决策基础。该机构进一步呼吁Capricor董事会主动探索包括并购、资产重组及其他战略替代方案在内的多种可能性，以提升股东价值。
通过引入独立董事并设立专门委员会，Kaos Capital希望推动Capricor在战略决策层面实现更高透明度与效率。目前，Capricor方面尚未对上述提名及建议作出公开回应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.